Jupiter Neurosciences launches Nugevia MND to support cognitive function and brain health

In an August 11, 2025, press release, clinical-stage pharmaceutical company Jupiter Neurosciences introduced Nugevia MND, a supplement designed to support cognitive function and brain health. Jupiter Neurosciences is the developer of the reservatrol-based technology, Jotrol, a delivery platform designed to improve bioavailability and permeation of the central nervous system. Nugevia MND is a combination of the NovaSOL Curcumin formulation and Jotrol, with the goals of reducing oxidative stress and inflammation, plus enhancing synaptic plasticity and offering potential neuroprotective effects against cognitive decline related to aging.

The supplement is directed to support older adults interested in cognitive maintenance with benefits listed in the press release to include enhanced memory, clarity, and executive function and support for mitochondrial function in brain cells.

“The introduction of Nugevia MND represents a strategic step in leveraging our CNS therapeutic expertise within the consumer health market,” added Christer Rosén, chairman and CEO of Jupiter Neurosciences, in the press release. “Importantly, learnings from consumer use of MND, combined with biomarker data anticipated from our upcoming Phase II Parkinson’s disease trial, will provide valuable insights to inform our future cognitive health programs. What is the purpose of all the new ways with early detection of these progressive diseases if there is no good way to prevent them, stop them, or significantly slow them down? We are optimistic that our clinical studies will back up my belief that we have again cracked the code and MND is the solution.”

In June 2025, the company announced the launch Nugevia, its line of performance and longevity supplements. The first three formulations in this line focused on mitochondrial support, mental clarity, and beauty-from-within. Last month, Jupiter Neurosciences launched the beauty-from-within supplement Nugevia GLO, designed to support skin hydration, cellular defense, and collagen integrity.

"We’ve worked extensively on our third, and in my opinion the most important, product in the Nugevia™ launch,” added Rosén. “It is my pleasure to introduce MND to the healthspan and longevity community. My mother passed away from Alzheimer’s Disease making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s Disease. This is personal, this is important and based on our Jotrol pharmaceutical pre-clinical and clinical date we are here to bring what we believe is the best cognition product to the market.”

The supplement is also anticipated to support Jupiter’s dual-path strategy focused on central nervous system (CNS) disorders and on the consumer longevity market, while addressing neuroinflammation and promoting healthy aging.

"MND not only reinforces our dual-path business strategy but also provides an immediate opportunity for revenue growth and meaningful data collection," explained Rosén. "Investors can be excited about the implications of a consumer product directly supporting our pharmaceutical development pipeline."

MND is expected to be available directly to consumers through e-commerce platforms in Fall 2025 as a two-capsule daily regimen.